FDA calls out Bristol Myers over cancer drug claims

The FDA has accused Bristol Myers Squibb of making false or misleading claims about its cancer drug, Krazati, particularly concerning its efficacy and impact on survival. The accusations stemmed from multiple complaints received via the FDA’s Bad Ad Program.